Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07309718
Recruiting Observational

MPR for Stroke Risk Assessment of ICAS

NCT07309718 · tracked via the Priya Life Science China tracker
Sponsor
Xuanwu Hospital, Beijing
Phase
Observational
Started
2025-12-01
Last updated
2025-12-30

Condition(s) studied

ICAS - Intracranial AtherosclerosisStroke IschemicHemodynamic

Investigational drug(s) / intervention(s)

Standardized medical therapy targeting vascular risk factors and stroke prevention

Standardized medical therapy targeting vascular risk factors and stroke prevention: Dual antiplatelet treatment and management of vascular risk factors, in accordance with AHA/ASA guidelines

Study summary

Intracranial atherosclerotic stenosis (ICAS) carries substantial stroke risk despite optimal medical treatment. Current risk stratification relies primarily on stenosis severity, but novel hemodynamic markers may improve prediction. In this multiple prospective registry study we aim to investigate whether regional hemodynamics, measured by a novel Magnetic resonance imaging-derived Pressure Ratio (MPR) technique, are associated with stroke risk in ICAS.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Adults aged 18 to 80 years. 2. Intracranial atherosclerotic stenosis ICAS involving a culprit artery in the anterior circulation. 3. Intracranial arterial stenosis of 50% to 99% as measured by the WASID method using TCD, CTA, MRA, or DSA. 4. Written informed consent obtained from the participant or a legal representative. Exclusion Criteria: 1. Non-atherosclerotic intracranial lesions, including moyamoya disease, vasculitis, vascular dissection, autoimmune diseases, or congenital/genetic abnormalities. 2. More than 50% stenosis of the extracranial carotid artery on the ipsilateral side. 3. Large cerebral infarction involving more than one-half of the territory on DWI imaging, or a baseline modified Rankin Scale score ≥3. 4. Contraindications to antiplatelet therapy or statins. 5. Inability to undergo MRI due to metal implants or claustrophobia.

Primary outcome measure(s)

  • ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment. — 12 months
    the number of participants who suffer from ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.

Trial sites (1)

FacilityCityRegionStatus
Department of Neurosurgery, Xuanwu hospital Beijing Xicheng District Recruiting

More Xuanwu Hospital, Beijing trials in China

Study on the Incremental Predictive Value of Early Resting-State EEG Phenotypes for Functional Prognosis and Risk Stratification in Acute Ischemic Stroke Starting soon
Research, Development, and Application of Intelligent Diagnostic System for Orthostatic Hypotension Starting soon
Implantable Vagus Nerve Stimulation Modulation of Coeruleus-Norepinephrine Network for Mild-Moderate AD Patients Starting soon
Effect of WBT for CI With Depression Recruiting
Effect of Intranasal Negative Pressure Therapy on Cognitive Function in Patients With Mild Cognitive Impairment and Obstructive Sleep Apnea Starting soon

Other trials for the same condition

BASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease Recruiting
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial Recruiting
Digital Angiography-Derived Fractional Flow Assessment for Intracranial Stenosis Active, not recruiting
Feedback Loop Between Intracranial Atherosclerosis and Cerebral Small Vessel Disease Recruiting
Advancing Reperfusion Therapy for Ischemic Stroke: Perfusion-guided Endovascular Intervention for Medium Vessel Occlusion Therapy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07309718 on ClinicalTrials.gov ↗ ← All trials in China